title: DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile.
abstract: This report describes the first evaluation in humans of DOV 216,303, a putative antidepressive that inhibits the reuptake of norepinephrine, serotonin, and dopamine. Subjects received single oral doses of 5 to 150 mg of DOV 216,303 or placebo. At 150 mg, 4 of 7 subjects reported gastrointestinal disturbances. In the multiple-dose phase of the evaluation, subjects received total daily doses of 50, 75, or 100 mg of DOV 216,303 or placebo for 10 days. At a total daily dose of 100 mg, gastrointestinal disturbances were reported in 4 of 6 volunteers. In both the single- and multiple-dose evaluations, no significant changes were noted in vital signs, electrocardiogram, hematology, or clinical chemistry. DOV 216,303 was rapidly absorbed (plasma t(max) of 0.7-1.2 hours and t(1/2) of 3.3-4.4 hours), with dose-proportional C(max) and AUC values. Furthermore, no remarkable difference was apparent in either the C(max) or AUC(tau) of DOV 216,303 following 1 and 10 days of dosing. The present results demonstrate that DOV 216,303 is safe and well tolerated both at single doses of up to 100 mg and multiple doses of up to 100 mg/day for 10 days. Plasma concentrations of DOV 216,303 after doses > 10 mg exceed its reported IC(50) values for inhibition of biogenic amine reuptake.
authors.affiliation: DOV Pharmaceutical, Inc, Continental Plaza, 433 Hackensack Avenue, Hackensack, NJ 07601, USA.
authors.forename: Bernard
authors.initials: B
authors.lastname: Beer
authors.forename: Jill
authors.initials: J
authors.lastname: Stark
authors.forename: Philip
authors.initials: P
authors.lastname: Krieter
authors.forename: Pal
authors.initials: P
authors.lastname: Czobor
authors.forename: Gary
authors.initials: G
authors.lastname: Beer
authors.forename: Arnold
authors.initials: A
authors.lastname: Lippa
authors.forename: Phil
authors.initials: P
authors.lastname: Skolnick
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000928:Antidepressive Agents / Q000737:chemistry / Q000145:classification / Q000627:therapeutic use; D019540:Area Under Curve; D001372:Aza Compounds / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics*; D002214:Capsules; D004064:Digestive System / Q000187:drug effects / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D006207:Half-Life; D006801:Humans; D008297:Male; D015394:Molecular Structure; D014179:Neurotransmitter Uptake Inhibitors / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics
chemical_list: C474071:1-(3,4-dichlorophenyl)-3-azabicyclo-(3.1.0)hexane hydrochloride; D000928:Antidepressive Agents; D001372:Aza Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D002214:Capsules; D014179:Neurotransmitter Uptake Inhibitors